Circulating CD14⁺ HLA-DR^lo/- monocytic cells as a biomarker for epithelial ovarian cancer progression.

ABSTRACT:

Problem

Previous studies identified circulating CD14⁺ HLA-DR^lo/- monocytic cells as an immune suppressive subset in solid malignancies, such as prostate, renal cell carcinoma, and pancreatic cancer. Such monocytic cells have been implicated not only in tumour progression but also as a potential barrier for immunotherapy. This study examined the relationship between the frequency of circulating monocytic cells and epithelial ovarian cancer (EOC) progression pre- and post-frontline chemotherapy, defined by disease stage, which is a leading prognostic factor for this malignancy.

Method of study

Incident cases of 236 women with EOC were recruited and comprehensive flow cytometry was utilized to assess the frequency of peripheral blood CD33⁺ CD11b

SUBMITTER: Stenzel AE 

PROVIDER: S-EPMC7897210 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature